BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
Almonty Industries Shares Jump 8% After Stifel Sets $25 Target 
DaVoice Sues Perplexity AI Over Trade Secrets 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
BlackBerry Shares Rise as Q2 Earnings, Revenue Beat Estimates 
US Appeals Court Upholds Anthropic AI Supply Chain Ban 
Apple Extends Qualcomm Patent Licensing Deal 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
US Backs Musk in Fight Against EU’s €120 Million X Fine 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
Solidigm Eyes $150 Billion IPO as SK Hynix Expands AI Storage Push 
OpenAI Agent Breaches Australia Medicare Data Portal 
Oracle Shares Fall as New Mexico AI Data Center Faces Power Delays 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals 
Add as a preferred source on Google
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
